jueves, 12 de mayo de 2016

May 24, 2016 Endocrinologic and Metabolic Drugs Advisory Meeting

Diabetes Monitor
Drugs Advisory Committee Meeting: Endocrinologic and Metabolic
Date: May 24, 2016
The committee will discuss the safety and efficacy of new drug application (NDA) 208583 for insulin degludec and liraglutide injection, submitted by Novo Nordisk Inc., for the proposed indication: adjunct to diet and exercise to improve glycemic control in the treatment of adults with type 2 diabetes mellitus. More information

Helene Clayton-Jeter, O.D.
Office of Health and Constituent Affairs
Food and Drug Administration

For more information about the Cardiovascular & Endocrine Liaison Program visit the FDA Patient Network

No hay comentarios:

Publicar un comentario